db/db 小鼠中PDE4抑制剂弗罗斯特和弗罗斯特N氧化物降糖效应

The cAMP-degrading phosphodiesterase 4 (PDE4) enzyme has recently been implicated in the regulation of glucagon-like peptide-1 (GLP-1), an incretin hormone with glucose-lowering properties. We investigated whether the PDE4 inhibitor roflumilast elevates GLP-1 levels in diabetic db/db mice and whether this elevation is accompanied by glucose-lowering effects.

Plasma GLP-1 was determined in db/db mice after single oral administration of roflumilast or its active metabolite roflumilast-N-oxide. Diabetes-relevant variables including HbA_1c, blood glucose, serum insulin, body weight, food and water intake, and pancreas morphology were determined in db/dbmice treate